Roadmap

Hemerion plans to add its technology within the Standard of Care in the US and Europe in 2026.
Our roadmap includes clinical trials and the regulatory processes with both the European Medicine Agency (EMA) and the Food & Drug Administration (FDA).

Glioblastoma is eligible for accelerated approval programs at the FDA. These regulatory fast tracks will speed-up our clinical development and Marketing Approval (MA) while supporting/developing parallel regulatory tracks at the EMA.

Pipeline